Skip to main content
Premium Trial:

Request an Annual Quote

Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton

NEW YORK (GenomeWeb) – Investment bank Bloom Burton & Co. is proving funding to Ontario-based personalized health firm Newtopia, the company announced today.

Bloom Burton's support follows the announcement in October that the international insurance underwriter Argo Group US will invest in Newtopia and use the company's personalized medicine services across its US employee base to reduce corporate healthcare costs.

Newtopia markets a platform that encourages people to make lifestyle changes based on genetic testing results, a mobile plan, a coach, and engagement with a social health community. The program is specifically aimed at employees at risk for metabolic syndromes, such as obesity, type 2 diabetes, heart disease, and stroke.

A year ago, the Aetna Innovation Lab said it would launch a pilot program involving 500 Aetna employees to gauge if Newtopia's genetic testing and coaching program could reduce their risk of metabolic syndromes over the period of a year. In this project, study participants receive a saliva-based test and learn about what their genes say about obesity, appetite, and behavior. Factoring in the test results and an online assessment, Newtopia crafts a personalized plan for each participant and matches them to a coach, who will help them maintain a healthy weight and engage them in a metabolic syndrome risk-reduction plan. The project investigators then measure the changes in patients' outcomes before and after the testing and coaching interventions.

According to Newtopia, its program focused on metabolic syndromes has already shown to positively impact people's health metrics and has reduced yearly medical costs.

Newtopia did not disclose the amount Bloom Burton is investing in the company. With Bloom Burton's support, Newtopia plans to expand its employee base and business growth strategies, it said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.